Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor

Next Previous
Trial Profile

A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chlormethine (Primary) ; Acitretin; Bexarotene; Bexarotene; Corticosteroids; Imiquimod; Romidepsin
  • Indications Cutaneous T-cell lymphoma; Mycosis fungoides
  • Focus Therapeutic Use
  • Acronyms PROVe
  • Sponsors Actelion Pharmaceuticals; Helsinn Therapeutics

Most Recent Events

  • 25 Apr 2021 Results assessing the tolerability of topical chlormethine gel in Mycosis Fungoides Cutaneous T-cell Lymphoma, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.
  • 18 Mar 2021 Results published in the Helsinn media release
  • 18 Mar 2021 According to a Helsinn media release, Ellen J. Kim is the principal investigator of this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top